These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35616746)

  • 1. ASO Author Reflections: Decrease of Albumin and Derived Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy Reflect the Worse Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
    Abe T; Oshikiri T; Goto H; Kato T; Horikawa M; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Kakeji Y
    Ann Surg Oncol; 2022 Oct; 29(11):6867-6868. PubMed ID: 35616746
    [No Abstract]   [Full Text] [Related]  

  • 2. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
    Ji WH; Jiang YH; Ji YL; Li B; Mao WM
    Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASO Author Reflections: Tumor Response After the First Course of Neoadjuvant Chemotherapy Reflects Prognosis After Surgery in Patients with Esophageal Squamous Cell Carcinoma.
    Hagi T; Shiraishi O; Yasuda T
    Ann Surg Oncol; 2024 Aug; 31(8):5310-5311. PubMed ID: 38702391
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: Association Between Preoperative Coagulation Status and Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma After Neoadjuvant Treatment.
    Sugiyama F; Kanda M; Kodera Y
    Ann Surg Oncol; 2024 May; 31(5):3473-3474. PubMed ID: 38261127
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Preservation of the Thoracic Duct is Feasible for Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy After Neoadjuvant Chemoradiotherapy.
    Oshikiri T; Numasaki H; Oguma J; Toh Y; Watanabe M; Muto M; Kakeji Y; Doki Y
    Ann Surg Oncol; 2023 May; 30(5):2699-2700. PubMed ID: 36629993
    [No Abstract]   [Full Text] [Related]  

  • 6. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma.
    Fu X; Li T; Dai Y; Li J
    BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASO Author Reflections: Response to Neoadjuvant Chemotherapy Strengthens the Prognostic Impact of Pathological Stage for Esophageal Squamous Cell Carcinoma.
    Matsuda S; Kawakubo H; Okamura A; Takahashi K; Toihata T; Takemura R; Mayanagi S; Takeuchi H; Watanabe M; Kitagawa Y
    Ann Surg Oncol; 2021 Dec; 28(13):8448-8449. PubMed ID: 34143335
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5895-5896. PubMed ID: 37266806
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: Prognostic Significance of Kallikrein-Related Peptidase 13 Induction After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Shimomura A; Yamada K; Kawamura YI
    Ann Surg Oncol; 2024 Jan; 31(1):243-244. PubMed ID: 37851200
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Okamura A; Matsuda S; Kawakubo H; Mine S; Takeuchi H; Kitagawa Y; Watanabe M
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):795-796. PubMed ID: 32591950
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Prediction of the Response to Neoadjuvant Therapy by Patients with Esophageal Squamous Cell Carcinoma.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Apr; 30(4):2186-2187. PubMed ID: 36538253
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutrophil-to-lymphocyte ratio change predicts histological response to and oncological outcome of neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Hoshino S; Takeuchi M; Kawakubo H; Kobayashi R; Matsuda S; Irino T; Fukuda K; Nakamura R; Kitagawa Y
    Esophagus; 2022 Jul; 19(3):426-435. PubMed ID: 35059908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin and Derived Neutrophil-to-Lymphocyte Ratio is a Novel Prognostic Factor for Patients with Esophageal Squamous Cell Carcinoma.
    Abe T; Oshikiri T; Goto H; Kato T; Horikawa M; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Nakamura T; Kakeji Y
    Ann Surg Oncol; 2022 Oct; 29(11):6860-6866. PubMed ID: 35622180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASO Author Reflections: Biomarkers for Neoadjuvant Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma.
    Okumura H; Noda M; Natsugoe S
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):715-716. PubMed ID: 30288651
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: Total Lesion Glycolysis Ratio in Positron Emission Tomography and Computed Tomography Images During Neoadjuvant Chemotherapy: Usefulness and Perspectives as an Evaluation Tool for the Effect of Neoadjuvant Treatment on Esophageal Squamous Cell Carcinoma.
    Sonoda A; Yoshida N; Baba H
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):806-807. PubMed ID: 32623607
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.
    Deng W; Chen J; Xiao Z
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):802-803. PubMed ID: 31654164
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: ypTNM Stage Grouping in the 8th Edition of the AJCC Cancer Staging Manual Refines the Prognostic Prediction for Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy.
    Sudo N; Ichikawa H; Muneoka Y; Hanyu T; Kano Y; Ishikawa T; Hirose Y; Miura K; Shimada Y; Nagahashi M; Sakata J; Kobayashi T; Bamba T; Nakagawa S; Kosugi SI; Wakai T
    Ann Surg Oncol; 2021 Feb; 28(2):661-662. PubMed ID: 33001302
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: How Should We Approach Borderline Resectable Esophageal Squamous Cell Carcinoma?
    Suzuki T; Okamura A; Watanabe M; Chin K
    Ann Surg Oncol; 2020 May; 27(5):1518-1519. PubMed ID: 32108921
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Refections: Evaluation of Endoscopic Response After Neoadjuvant Chemotherapy Guides Distribution of Residual Diseases for Esophageal Squamous Cell Carcinoma.
    Matsuda S; Kawakubo H; Tsuji T; Aoyama J; Hirata Y; Takemura R; Mayanagi S; Irino T; Fukuda K; Nakamura R; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2022 Apr; 29(4):2681-2682. PubMed ID: 34762213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.